Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear you but nobody wants 1 share at .40 either......
Because you cant buy many shares down below 50 cents. This is for larger investors. Any large buying will make this run hard IMHO. The problem for now is hat there is no buying.
Why buy at .50 when you can buy at .40?
Someone selling at .40..............
Couldn't agree more!!!!!!!!!!!!!
I can wait longer but the filling at fifty cents has me uneasy.
People are willing to sell beneath it.
I hope they pull it!!!!!
Maybe they shoudl consider getting some depth rather than equity. One shareholder is giving them a loan, so maybe this could make more sense.
Certainly not helping the insiders selling their shares at $0.5. But maybe they will cancel the S1, that would really help us going back up quickly. Just a thought.
Somebody is picking up the shares at very low prices. Impatient seller hitting the bid price..... at 50% off.
Somebody not willing to wait some more I guess. The filing didnt have any large surprise in it. As far as I can tell.
Didn't see it but somebody doesn't like it - down 45%......
Hopefully - I am holding my shares as well but we might be holding them for a very long time!!!!!!
Well, I guess we are getting rid of weak and impatient shareholders. Will keep my shares looking for higher prices in the future. Not much of a downside from here IMHO.
I got to be honest - I don't see YBGJ ever going up.
If you feel differently, please tell me why?
Not a buyer in sight!!!!!!!!!!!!!!!!!!!!
Thank you as always POTSE for your in-depth analysis.
Who is going to buy all that stock at .50?
I wish I could but I am not the person.
You probably own more of YBGJ than I do, so I hope you become phenomenally wealthy.
S-1/A items/observations, VIV-CELL store opening......
1) Based on some of the numbers/info in the paragraphs below, I think Q2 will probably continue to be low. Some quick/rough back-of-the-envelope calculations is leading me to believe it will probably be somewhere above $300K........
Respiratory atomization products (nebulizers): include lung regulating essence, which is applied through an atomizer and formulated on the basis of multiple growth factors rich in the polypeptide of cell technology such as FGF, EGF, VEGF, etc. to repair and cure the lungs. Our products can enhance the regeneration of lung stem cells, inhibit apoptosis of normal lung cells, improve immunity, relieve dry and astringent foreign body sensation, and relieve chest tightness, chest pain, wheezing, breathing difficulties and other symptoms. We launched our respiratory atomization products in April 2020 and the sales of these products have accumulated to approximately $1.7 million since launch. Our respiratory atomization products are sold in Guangdong, Shandong, Hebei, Henan, Chongqing and Sichuan provinces. The customer base for these products mainly includes middle class and above population with respiratory system diseases or weaknesses, or low immunity.
Cell basidiomycetes compound drink/beverage: This product is registered as beverage. Based on cellular immunology, combined with traditional Chinese medicine theories and natural plant extracts such as basidiomycetes, red ginseng and polygonatum, it has the benefits of rapid activation of immune cells, regulation of immune system, anti-tumor, anti-virus, hypoglycemic and anti-oxidation. We launched our cell basidiomycetes compound drink in February 2021 and the sales of this product have accumulated to approximately $400,000 by end of May 2021. We are still in the process of promoting this product to cover more regional markets. The customer base for this drink mainly includes middle class and above population who are recovering from major epidemic diseases or with low immunity.
We currently employ 20 employees at our headquarters, located at Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, PRC. Our employees include three executive officers, two financial department personnel, two administrative management personnel, six R&D and product personnel, six planning and marketing personnel, and one person in IT management. With the expansion of our business and establishment of our stem cell bank in Chengdu, China, we plan to increase our recruitment efforts in the fields of technology, research and development and marketing, and we expect to employ approximately 60 employees in 2022. In order to attract, retain and reward top talents in the industry, we are considering establishing various incentive program for our employees, and we may establish an equity incentive plan in the future.
On May 11, 2021, we entered into a verbal loan agreement with World Precision Medicine Technology Inc., a company owned and controlled by Cheung Ho Shun, one of our existing shareholders, which provided the Company with a working capital loan in the principal amount of $600,000. The loan is due on demand and non-interest bearing.
On the morning of July 25, 2021, the opening ceremony of VIV-CELL Yubo Biotechnology Experience Center was grandly held in Qingdao Belle Plaza.
Another S1 ammendment filed today. Not sure about the changes yet.
Another S1 ammendment filed today. Not sure about the changes yet.
No, but nobody wants to buy any at .50 in the open market either.
So disappointed!!!!!!!!!!!!!
Does anyone have any indication on how the S-1 share sales are going? Any other news in regards to YBGJ?
Well the later gets them a higher price for their shares.
As it is, I'm skeptical they will get anybody to buy at half a dollar.
Hope I'm wrong!!!!!!!!!!
There is reason to do it both ways, I guess.
Wouldn't it make more sense to do it the other way around?
Talk about their business to move share price higher and then place shares.
Nobody knows about this company and they are being silent so far, e.g. no press releases. They might place their shares first and then start talking about their business to move share price higher. Could make sense IMHO.
Hope you're right.
It's seems bizarre than no retail investors wants to bid for any......
The 12M shares will be sold to some larger investors, not over the exchange. If they sell those shares to some larger invetors this will give the share price a boost. Since the float being traded over the stock exchange is rather small, the induced buying of shares can move the stock quickly. Ever looked at shares going public. They buy the shares prior to going public at a large discount to how they trade over the exchange, once traded.
Move quickly - YBGJ trades a couple of shares a day at best and now there are 12M for sale.
How in the world is this going to move quickly?
I understand. I also liked the shares better above $3, but hey these shares can move quickly. Lets hope they prove to be a good investment, time will tell. Dont see many shares being offered/sold in the market either...
I don't share your enthusiasm but do hope there is a large potential here.
Might be a low float but that is about to go up by 12M. shares.
Institutional investors. Try to buy 12 million shares at 26 cents, impossible. No real selling taking place, the number of floating shares is low that is why there is little to no trading. Current share price isnt reflecting much of anything. I would like to hear from management and prices should move. This might take a while but I do see a large potential here IMHO.
Serious question - by who?
The best bidder is 26 cents.
Who is going to buy 17M at a half a dollar, especially when 12M are by selling shareholders.
If they don't want it, why would anybody else?
Thanks
Dont really see any big changes. Lets hope for those S1 shares to be picked up quickly.
Any differences?
The S1 was already filed on May 6th, so this is S1 ammended.
S-1 filled today - any thoughts?
If I am reading this right, this puts a lid on YBGJ at 50 cents - if I am right this really sucks!!!!!!!!!!
Is the company offering 5M shares and selling shareholders over 12M of which he company is not going to see a penny?
We are offering, on a “best efforts” basis, up to an aggregate of 5,000,000 shares of our Class A common stock, par value 0.001 per share , at a fixed price of $0.50 per share. Our shares of Class A common stock are quoted on the OTC Marketplace under the symbol “YBGJ”. On July 9, 2021, the closing price of our Class A common stock on the OTC Marketplace was $0.65 per share.
Additionally, the selling stockho lders are offering an additional 12,251,100 shares of Class A common stock, par value 0.001 per share, at a fixed price of $0.50 per share . The selling stockholders include: (i) Focus Draw Group Limited (“Focus”), which is selling up to 4,728,000 shares of our Class A common stock held by Focus (the “Focus Shares”), (ii) Dragoncloud Technology Limited (“Dragoncloud”), which is selling up to 5,768,100 shares of our Class A common stock held by Dragoncloud (the “Dragoncloud Shares”), and (iii) Cheung Ho Shun (“Cheung”), who is selling up to 1,755,000 shares of our Class A common stock held by Cheung (the “Cheung Shares”). The Focus Shares, the Dragoncloud Shares and the Cheung Shares are referred to collectively as the “Resale Securities”
So we got an ammended S1 today, kind of hard to tell the difference.
Thank you Potse for your thoughtful analysis!
A couple observations...Q1, S-1......
Q1: First quarter revenue ($462K) and gross margin (68%) were down from the fourth quarter. I would have preferred to see those numbers a little bit higher, but it doesn't overly concern me at the moment. I'm hoping to see some additional growth/acceleration more toward the Q3/Q4 timeframe. I'm not entirely sure if the products were just recently launched/introduced or if the company is just bringing more attention to them (I'm thinking the former) but, YBGJ-related social media accounts in China the last week or two seemed to be focused on two light-application products (skin/hair treatments).
S-1: It is kind of interesting to note how the intense selling pressure that was being exerted on the stock seemed to significantly decrease as soon as the S-1 was filed on May 6. There appears to be much less interest now in selling under that 50-cent price area. It will probably take at least a couple/few months for the S-1 to be declared effective. It will be interesting to see if YBGJ is arranging for institutional involvement in the proposed $2.5 financing and potential insider sales. I think is reasonable to assume will see increased volume in the stock and perhaps increased corporate activity later this year with the financing once the S-1 becomes effective.
I only had time to have a short glance at it, so far nothing unexpected as far as I can tell.
Never looked at their filings before.
What's with the Class B Common Shares?
Since it is a RM how do you compare the results?
Actually I don't have any thoughts. Do you?
For now.
The MM's are all over the place on this one....
Thank you for your well done research! I very much appreciate your quality posts here.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
328
|
Created
|
02/19/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |